Behçet Syndrome
📧 Sign up to get email alerts when something new happens for Behçet Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-20EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.
The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and…
-
EMA approval · 2026-03-04EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.
The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Lenalidomide in the Treatment of Mucosal Behçet's Syndrome [NA]
Clinical trial update indicates lenalidomide is being studied for mucosal Behçet's syndrome, with recruitment ongoing for oral ulcers.
-
CLINICAL_TRIALS research · 2025-07-18Clinical Trial Update: Prospective Multiethnic Validation of the Behçet's Syndrome Overall Damage Index (BODI)
This clinical trial update describes a prospective multiethnic validation study of the Behçet's Syndrome Overall Damage Index (BODI) to asse…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: AutoInflammatory Disease Alliance Registry (AIDA)
The AutoInflammatory Disease Alliance Registry (AIDA) is currently recruiting to collect data on hereditary autoinflammatory diseases. The c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-01-06EMA Application withdrawn: Apremilast Viatris (apremilast) — Viatris Limited
The European Medicines Agency has withdrawn Viatris Limited's application for apremilast (Viatris) for the EU market, terminating the market…
-
FDA approval · 2024-04-29FDA Approved: COLCHICINE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals’ generic colchicine under an original ANDA, authorizing its marketing as a generic product.
-
CLINICAL_TRIALS trial_result · 2014-08-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease [Phase 2]
Phase 2 trial assessing efficacy and safety of apremilast (CC-10004) for Behçet disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2010-08-16Clinical Trial Update: Psychological Symptoms in Patients With Behcet's Disease by SCL90-R
This completed clinical trial from Tehran University of Medical Sciences assessed psychological symptoms in Behçet's syndrome patients using…